Asahi Kasei

Activities: Manufacturing Ingredients

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Manufacturing

Asahi Kasei offers novel microcrystalline cellulose to combat nitrosamine impurities

Nitrite levels in the product are 0.1 μg/g (ppm) or less
Manufacturing

AGC Biologics partners with Asahi Kasei Pharma Corporation on antibody project

Asahi has been chosen by AGC Biologics for its monoclonal antibody development and manufacturing experience to perform process transfer, process optimisation, and clinical manufacturing of the Asahi Kasei Pharma drug substance
Manufacturing

Second plant for Ceolus microcrystalline cellulose completed by Asahi Kasei

Completed in January 2023, the new facility underlines the company's commitment to meet the substantially growing demand for its MCC
Regulatory

Auxilium receives US$10m milestone payment from Asah Kasei Pharma

After successful application to PMDA for Xiaflex
Manufacturing

Asahi Kasei launches BioOptimal MF-SL microfilters

Offer improved efficiency of protein harvest process

Actelion profits to take US$80m hit after fasudil ruling

<p>Swiss biopharmaceutical firm Actelion is forecasting a US$80m hit to its 2009 operating profit after an arbitration panel ruled against its subsidiary CoTherix in a dispute with pharmaceutical firm Asahi Kasei Pharma regarding a licence to develop the Japanese firm\'s rho kinase inhibitor, fasudil. </p>
Subscribe now